Tim Harris
![Tim Harris](https://oc-static.poweredbyproctors.co.uk/public/images/24/03/18/Tim.Harris.png?VersionId=ETbMamKsSXm4K0rJGbOruyu4hbOxZiti)
It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field allied to his scientific training, Tim is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today Tim's principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Court and Unified Patents Court principally to innovator biotech and pharma companies. Tim has advised on numerous blockbuster treatments including monoclonal antibody therapies and other biologics, as well as other innovative technologies.
Tim enjoys helping his clients understand, enforce and defend their IP rights and minimise their risks. The approach taken to this work is always collaborative, often working as part of a multi-jurisdictional team he relishes the challenge of forming and deploying creative legal and commercial strategies.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
I enjoy developing and supporting the next generation of lawyers and entrepreneurs. I take pleasure from regularly lecturing, teaching, and working with start-ups and spin-outs to help them understand how to protect their innovations and minimise IP risks.
The government has signalled its intention to pave the way for gene-edited crops following a consultation on departing from EU...
Details on the funding of the 10-year strategy, which builds on the UK's world-class capability and on lessons from the...
An artificial intelligence (AI) machine cannot be an 'inventor' for purpose of Patents Act 1977 and owner of machinery cannot...
The ancient form of power generation is now the world's number two source of renewable electricity, and its high profile...
The decision provides a further example that the UK courts are likely to accept the Formstein defence, when required, and...
An upsurge in patent filings by new competitors in the autonomous vehicles arena means incumbents need to strengthen their IP...
Does a proposed patent suspension backed by Washington open a Pandora's box for vaccine R&D and investment?
This decision shows the court assessing patentability in a real-world practical context, recognising the uncertainties of R&D that only later...
Pressure for an IP rights waiver to fight the pandemic threatens vaccine companies' ability to develop and protect their trade...